4.7 Article

Risk Stratification for Pacemaker Implantation after Transcatheter Aortic Valve Implantation in Patients with Right Bundle Branch Block

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 19, Pages -

Publisher

MDPI
DOI: 10.3390/jcm11195580

Keywords

TAVI; permanent pacemaker implantation; right bundle branch block

Funding

  1. Open Access Publication Fund of the University of Freiburg
  2. Daiichi Sankyo
  3. Astra Zeneca
  4. Sanofi-Aventis
  5. Bayer
  6. Medicines Company
  7. Bristol
  8. Novartis
  9. Roche
  10. Boston Scientific
  11. Biotronik
  12. Medtronic
  13. Edwards
  14. Ferrer
  15. Abiomed
  16. Abbott Diagnostics
  17. AstraZeneca
  18. Edwards Lifescience

Ask authors/readers for more resources

Patients with pre-existing RBBB undergoing TAVI have a high risk of PPI. Within this subgroup, female patients, male patients treated with self-expandable valve types, patients with high load/degree of non-coronary LVOT calcification, and patients with atrial fibrillation need enhanced surveillance for CD after the procedure.
Background: Permanent pacemaker implantation (PPI) after transcatheter valve implantation (TAVI) is a common complication. Pre-existing right bundle branch block (RBBB) is a strong risk factor for PPI after TAVI. However, a patient-specific approach for risk stratification in this subgroup has not yet been established. Methods: We investigated TAVI patients with pre-existing RBBB to stratify risk factors for PPI and 1-year-mortality by detailed analysis of ECG data, RBBB morphology and degree of calcification in the implantation area assessed by computed tomography angiography. Results: Between 2010 and 2018, 2129 patients underwent TAVI at our institution. Among these, 98 pacemaker-naive patients with pre-existing RBBB underwent a TAVI procedure. PPI, because of relevant conduction disturbances (CD), was necessary in 43 (43.9%) patients. PPI was more frequently indicated in women vs. men (62.1% vs. 32.8%, p = 0.004) and in men treated with a self-expandable vs. a balloon-expandable valve (58.3% vs. 26.5%, p = 0.035). ECG data (heart rhythm, PQ, QRS, QT) and RBBB morphology had no influence on PPI rate, whereas risk for PPI increased with the degree of calcification in the left septal His-/left bundle branch-area to a 9.375-fold odds for the 3rd tertile of calcification (1.639-53.621; p = 0.012). Overall, 1-year-mortality was comparable among patients with or without PPI (14.0% vs. 16.4%; p = 0.697). Conclusions: Patients with RBBB undergoing TAVI have a high risk of PPI. Among this subgroup, female patients, male patients treated with self-expandable valve types, patients with high load/degree of non-coronary LVOT calcification and patients with atrial fibrillation need enhanced surveillance for CD after procedure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available